|
Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. |
|
|
No Relationships to Disclose |
|
Stephen Anthony Strickland |
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Baxalta; Boehringer Ingelheim; CTI; Daiichi Sankyo; Sunesis Pharmaceuticals |
Research Funding - Abbvie; Astellas Pharma; Boehringer Ingelheim; Celator; Cyclacel; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi; Sunesis Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Agios; Amphivena; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Janssen; MEI Pharma; Roche; Shire |
Research Funding - Abbvie (Inst); Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); CTI (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst) |
Travel, Accommodations, Expenses - Amphivena; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Celator; Incyte; MEI Pharma; Roche; Shire |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Celgene; Novartis; Servier |
Research Funding - Celgene; Servier |